Cuban Ecosystem

The Cuban Science and Technological Innovation System for Health (SCITS) is singular and all-inclusive, and guided by two principles: the interdependence of education, services and research; and the integration of scientific advances into social practice.

Approximately 26% of all Cuban scientific institutions are dedicated to health-related research, development and innovation, and are linked mainly to the Ministry of Public Health (MINSAP), the Group of Biotechnology and Pharmaceutical Industries (BioCubaFarma), (universities) and/or other sectors. MINSAP sets the health sector’s priorities in accordance with the country’s economic and social policy guidelines. The State provides funding to carry out research, innovation and development programs and projects at all levels.

BioCubaFarma is self-financed and conceives scientific research not only as a producer of knowledge but also as a source of material and financial resources for recouping investments without neglecting its social commitment to public health. The Cuban population’s access to high quality medical care is made possible by the integration of research centers with science and technology services delivery centers, development and innovation units, universities and health care institutions. Medicines, services and high-tech products are also accessible to population groups requiring them, without tangible costs and with a positive effect on their health.

One of BioCubaFarma’s main contributions to the cluster might be its demonstrated effectiveness in performing clinical trials due to its capability to articulate efforts with the National Clinical Trials Coordinating Center (CENCEC) and the specialized Hospitals, at an affordable cost. Furthermore, BioCubaFarma has active channels for distributing Biopharmaceutical Products in more than 40 countries, especially in Latin America.


The Group of Biotechnology and Pharmaceutical Industries in Cuba, BioCubaFarma, is a Holding which integrates 46 companies (33 in Cuba and 13 abroad) dedicated for more than 35 years to scientific development, research, production and commercialization into domestic and international markets of biopharmaceuticals, medical equipment and other products for human and animal health, as well as for agriculture.

BioCubaFarma companies develop and manufacture products in 21 facilities devoted to R&D and 112 production lines. The Group has a consolidated international presence, with more than 760 marketing approvals in almost 60 countries (mainly in Latin America, Asia and Africa), more than 2,300 patents granted worldwide, and exports to more than 40 countries.

BioCubaFarma constitutes a strategic sector in Cuba, developed on a solid scientific basis and high-qualified human resources (more than 17,000 employees), in order to raise the quality of life of our population and becoming a source of economic growth for the country, from our extensive projects and products pipeline.

Our portfolio is composed by:

Our companies have successfully performed Technology Transfer Agreements of biopharmaceutical products to several countries like Brazil, Vietnam, India, Venezuela, Algeria and China, among others, especially in the framework of South-South cooperation.

We also have long-term experience in incorporating joint ventures companies. There are six with foreign partners based in China, Singapore, Thailand and Spain as well as two in the Mariel Special Development Zone in Cuba. BioCubaFarma is open to negotiate diverse business models, including foreign investment in Cuba (to increase manufacturing capacities for expanding exports) and co-development of our wide portfolio of innovative projects (granting marketing rights in certain territories).

BioCubaFarma is committed to strengthening a network of international alliances!
The programme is co-financed by the Slovenian Enterprise Fund and the European Union, namely from the European Fund for Regional Development. It is carried out on the basis of the Substantial Support of Fund Recipients (SME) programme from 2018 to 2023 within the framework of the Operational Programme for the Implementation of European Cohesion Policy from 2014 to 2020.